Pfizer has launched a second lawsuit targeting Novo Nordisk and the obesity biotech startup Metsera, claiming that Novo Nordisk’s efforts to acquire Metsera are anticompetitive practices.
Back
Pfizer has launched a second lawsuit targeting Novo Nordisk and the obesity biotech startup Metsera, claiming that Novo Nordisk’s efforts to acquire Metsera are anticompetitive practices.